Perspective Therapeutics Files 8-K
Ticker: CATX · Form: 8-K · Filed: Nov 21, 2024 · CIK: 728387
Sentiment: neutral
Topics: corporate-update, sec-filing, medical-devices
TL;DR
Perspective Therapeutics (formerly IsoRay) filed an 8-K on Nov 21, 2024. Standard update.
AI Summary
Perspective Therapeutics, Inc. (formerly IsoRay, Inc.) filed an 8-K on November 21, 2024, reporting other events and financial statements. The company, incorporated in Delaware, is based in Seattle, Washington, and operates in the surgical and medical instruments sector. This filing follows a name change from IsoRay, Inc. in 2018.
Why It Matters
This 8-K filing indicates that Perspective Therapeutics, Inc. is providing updated corporate and financial information to the SEC, which is standard practice for publicly traded companies.
Risk Assessment
Risk Level: low — This filing is a routine 8-K for corporate updates and does not appear to contain significant new financial or operational information that would immediately impact risk.
Key Numbers
- 001-33407 — SEC File Number (Identifies the company's filing with the SEC.)
- 41-1458152 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Perspective Therapeutics, Inc. (company) — Registrant
- IsoRay, Inc. (company) — Former company name
- November 21, 2024 (date) — Date of earliest event reported
- Seattle, Washington (location) — Principal executive office location
- Delaware (location) — State of incorporation
FAQ
What is the primary business of Perspective Therapeutics, Inc.?
Perspective Therapeutics, Inc. is in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry, SIC code 3841.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on November 21, 2024.
What was the company's former name?
The company's former name was IsoRay, Inc., with a date of name change in 2018.
Where is the principal executive office of Perspective Therapeutics, Inc. located?
The principal executive office is located at 2401 Elliott Avenue, Suite 320, Seattle, Washington, 98121.
What is the state of incorporation for Perspective Therapeutics, Inc.?
Perspective Therapeutics, Inc. is incorporated in Delaware.
Filing Stats: 485 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2024-11-21 07:30:14
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value CATX NYSE American LLC
Filing Documents
- catx-20241121.htm (8-K) — 41KB
- catx-ex99_1.htm (EX-99.1) — 43KB
- catx-ex99_2.htm (EX-99.2) — 40KB
- img236230851_0.jpg (GRAPHIC) — 57KB
- catx-ex99_2s1.jpg (GRAPHIC) — 162KB
- catx-ex99_2s2.jpg (GRAPHIC) — 654KB
- catx-ex99_2s3.jpg (GRAPHIC) — 357KB
- catx-ex99_2s4.jpg (GRAPHIC) — 247KB
- catx-ex99_2s5.jpg (GRAPHIC) — 333KB
- catx-ex99_2s6.jpg (GRAPHIC) — 292KB
- catx-ex99_2s7.jpg (GRAPHIC) — 261KB
- catx-ex99_2s8.jpg (GRAPHIC) — 133KB
- catx-ex99_2s9.jpg (GRAPHIC) — 359KB
- catx-ex99_2s10.jpg (GRAPHIC) — 378KB
- catx-ex99_2s11.jpg (GRAPHIC) — 404KB
- catx-ex99_2s12.jpg (GRAPHIC) — 308KB
- catx-ex99_2s13.jpg (GRAPHIC) — 544KB
- catx-ex99_2s14.jpg (GRAPHIC) — 286KB
- catx-ex99_2s15.jpg (GRAPHIC) — 159KB
- catx-ex99_2s16.jpg (GRAPHIC) — 343KB
- catx-ex99_2s17.jpg (GRAPHIC) — 362KB
- catx-ex99_2s18.jpg (GRAPHIC) — 341KB
- catx-ex99_2s19.jpg (GRAPHIC) — 469KB
- catx-ex99_2s20.jpg (GRAPHIC) — 261KB
- catx-ex99_2s21.jpg (GRAPHIC) — 185KB
- catx-ex99_2s22.jpg (GRAPHIC) — 162KB
- catx-ex99_2s23.jpg (GRAPHIC) — 318KB
- catx-ex99_2s24.jpg (GRAPHIC) — 247KB
- catx-ex99_2s25.jpg (GRAPHIC) — 259KB
- catx-ex99_2s26.jpg (GRAPHIC) — 252KB
- catx-ex99_2s27.jpg (GRAPHIC) — 194KB
- catx-ex99_2s28.jpg (GRAPHIC) — 293KB
- catx-ex99_2s29.jpg (GRAPHIC) — 324KB
- catx-ex99_2s30.jpg (GRAPHIC) — 188KB
- catx-ex99_2s31.jpg (GRAPHIC) — 101KB
- catx-ex99_2s32.jpg (GRAPHIC) — 405KB
- catx-ex99_2s33.jpg (GRAPHIC) — 236KB
- catx-ex99_2s34.jpg (GRAPHIC) — 296KB
- catx-ex99_2s35.jpg (GRAPHIC) — 106KB
- 0000950170-24-129487.txt ( ) — 14407KB
- catx-20241121.xsd (EX-101.SCH) — 23KB
- catx-20241121_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On November 21, 2024, Perspective Therapeutics, Inc. issued a press release and posted to its website a presentation announcing certain initial results from its Phase 1/2a study of [ 212 Pb]VMT--NET for the treatment and diagnosis of patients with somatostatin receptor subtype 2-expressing neuroendocrine tumors (NETs) that are being presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium taking place from November 21-23, 2024 in Chicago, Illinois. A copy of the press release is filed herewith as Exhibit 99.1, and a copy of the presentation is filed herewith as Exhibit 99.2, and each is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated November 21, 2024 . 99.2 Investor Presentation . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PERSPECTIVE THERAPEUTICS, INC. Date: November 21, 2024 By: /s/ Johan (Thijs) Spoor Johan (Thijs) Spoor Chief Executive Officer